Day: September 11, 2022

VANCOUVER, British Columbia, Sept. 11, 2022 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) announces that the Kainantu Gold Mine, located in Eastern Highlands Province, Papua New Guinea is operating normally after experiencing a large earthquake yesterday. On September 11 at 9:46 am Papua New Guinea time, a 7.6 magnitude earthquake was recorded approximately 65 km east of the mine site and at a depth of 90 km. According to our protocols, operations were briefly suspended to complete the inspection of the underground mine, surface infrastructure and the health and wellbeing of our personnel. We are pleased to report that the underground was inspected and promptly cleared to resume operation. Surface infrastructure, including the Tailings Storage Facility which has specialized monitoring equipment...

Short-term contract extension for Petróleo Nautipa BW Offshore has entered into a short-term extension for Petróleo Nautipa, extending production from 20 September to 4 October 2022 ahead of demobilisation. For further information, please contact:Ståle Andreassen, CFO, +47 91 71 86 55Anders S. Platou, Head of Corporate Finance & Strategy, +47 99 50 47 40 IR@bwoffshore.com or www.bwoffshore.com About BW Offshore:BW Offshore engineers innovative floating production solutions. The Company has a fleet of 10 FPSOs with potential and ambition to grow. By leveraging four decades of offshore operations and project execution, the Company creates tailored offshore energy solutions for evolving markets world-wide. BW Offshore has around 2,000 employees and is publicly listed on the Oslo Stock Exchange. This information is subject to the disclosure...

88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at the pivotal dose Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023 Relay Therapeutics to host a conference call on Monday, September 12, at 8:00 am E.T. CAMBRIDGE, Mass., Sept. 11, 2022 (GLOBE NEWSWIRE) — Relay Therapeutics, Inc. (Nasdaq: RLAY) today announced late breaking interim clinical data in an oral presentation for RLY-4008, an investigational, potent, selective and oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), in a global phase 1/2 clinical trial in patients with FGFR2-altered CCA and multiple other solid tumors. The interim data presented today at the European Society for Medical Oncology (ESMO) Congress...